Skip to main
AMGN
AMGN logo

Amgen (AMGN) Stock Forecast & Price Target

Amgen (AMGN) Analyst Ratings

Based on 13 analyst ratings
Hold
Strong Buy 8%
Buy 31%
Hold 54%
Sell 8%
Strong Sell 0%

Bulls say

Amgen's positive outlook is supported by a robust commitment to research and development, with management guiding for over 20% R&D growth in 2025 compared to 2024, an increase from earlier expectations. The significant sales growth of Uplizna, showing a 58% increase in June 2025 compared to the previous quarter and a 40% jump from the same period in 2024, further underscores the company’s strong market position and successful product launches. Additionally, the continuation of pipeline advancements suggests a favorable scenario for multiple expansion, with an expected EV/2026E EBITDA of approximately 13 times, indicating strong potential for future earnings growth.

Bears say

Amgen's financial outlook is concerning due to its reliance on a narrow range of flagship products, which face increasing competition and potential market saturation, particularly as patent expirations loom. Despite recent acquisitions and product launches aimed at diversifying its portfolio, the company's revenue growth has been stunted, prompting worries about its ability to maintain profitability in the long term. Additionally, the rise of biosimilars and the impact of regulatory pressures on pricing strategies further exacerbate the challenges Amgen faces in sustaining its competitive edge within the biotechnology sector.

Amgen (AMGN) has been analyzed by 13 analysts, with a consensus rating of Hold. 8% of analysts recommend a Strong Buy, 31% recommend Buy, 54% suggest Holding, 8% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Amgen and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Amgen (AMGN) Forecast

Analysts have given Amgen (AMGN) a Hold based on their latest research and market trends.

According to 13 analysts, Amgen (AMGN) has a Hold consensus rating as of Nov 7, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $315.15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $315.15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Amgen (AMGN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.